EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening.
Cappelletto A, Alfì E, Volf N, Vu TVA, Bortolotti F, Ciucci G, Vodret S, Fantuz M, Perin M, Colliva A, Rozzi G, Rossi M, Ruozi G, Zentilin L, Vuerich R, Borin D, Lapasin R, Piazza S, Chiesa M, Lorizio D, Triboli L, Kumar S, Morello G, Tripodo C, Pinamonti M, Piperno GM, Benvenuti F, Rustighi A, Jo H, Piccolo S, Del Sal G, Carrer A, Giacca M, Zacchigna S.
Cappelletto A, et al. Among authors: del sal g.
J Exp Clin Cancer Res. 2024 Jan 10;43(1):15. doi: 10.1186/s13046-023-02942-4.
J Exp Clin Cancer Res. 2024.
PMID: 38195652
Free PMC article.